Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1412612,elimination half-life,"Preliminary pharmacokinetic data in humans indicate that the plasma drug disappearance curve was biphasic with a mean elimination half-life of 10.6 +/- 1.7 h, total clearance rate of 11.1 +/- 0.4 ml/min/m2, and area under the plasma drug concentration-time curve of 1,289-1,546 ng-h/ml.",Determination of plicamycin in plasma by radioimmunoassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412612/),h,10.6,1192,DB01005,Hydroxyurea
,1412612,total clearance rate,"Preliminary pharmacokinetic data in humans indicate that the plasma drug disappearance curve was biphasic with a mean elimination half-life of 10.6 +/- 1.7 h, total clearance rate of 11.1 +/- 0.4 ml/min/m2, and area under the plasma drug concentration-time curve of 1,289-1,546 ng-h/ml.",Determination of plicamycin in plasma by radioimmunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412612/),[ml] / [m2·min],11.1,1193,DB01005,Hydroxyurea
,1412612,area under the plasma drug concentration-time curve,"Preliminary pharmacokinetic data in humans indicate that the plasma drug disappearance curve was biphasic with a mean elimination half-life of 10.6 +/- 1.7 h, total clearance rate of 11.1 +/- 0.4 ml/min/m2, and area under the plasma drug concentration-time curve of 1,289-1,546 ng-h/ml.",Determination of plicamycin in plasma by radioimmunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412612/),[ng-h] / [ml],"1,289-1,546",1194,DB01005,Hydroxyurea
,1781415,elimination half-life,Results of these studies indicated that zileuton was well absorbed orally with an elimination half-life of approximately 2.5 hours.,"Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1781415/),h,2.5,16608,DB01005,Hydroxyurea
,26615061,"AUC(0,∞)","The mean target AUC(0,∞) for initial dose titration was 115 mg l(-1) h.",Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26615061/),[h·mg] / [l],115,20694,DB01005,Hydroxyurea
<,15778424,CL(cr),"On the basis of the exposure and the apparent clearance from the current and 2 historical studies, the authors have proposed an initial dosing regimen of hydroxyurea (7.5 mg/kg/day) for SCD patients with CL(cr) <60 mL/min.",The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15778424/),[ml] / [min],60,31632,DB01005,Hydroxyurea
,9653933,flow-rate,A flow-rate of 0.8 ml/min was used for analyzing HU in both human and mouse plasma.,New isocratic high-performance liquid chromatographic procedure to assay the anti-sickling compound hydroxyurea in plasma with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653933/),[ml] / [min],0.8,35524,DB01005,Hydroxyurea
,1848634,IC50,"Zileuton [N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyure] inhibited 5-hydroxyeicosatetraenoic acid synthesis by rat basophilic leukemia cell 20,000 x g supernatant and rat polymorphonuclear leukocytes (PMNL) (IC50 = 0.5 and 0.3 microM) respectively.",5-lipoxygenase inhibitory activity of zileuton. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848634/),μM,0.5,38805,DB01005,Hydroxyurea
,1848634,IC50,"Zileuton [N-(1-benzo[b]thien-2-ylethyl)-N-hydroxyure] inhibited 5-hydroxyeicosatetraenoic acid synthesis by rat basophilic leukemia cell 20,000 x g supernatant and rat polymorphonuclear leukocytes (PMNL) (IC50 = 0.5 and 0.3 microM) respectively.",5-lipoxygenase inhibitory activity of zileuton. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848634/),μM,0.3,38806,DB01005,Hydroxyurea
,1848634,IC50,"It also inhibited leukotriene (LT)B4 biosynthesis by rat PMNL (IC50 = 0.4 microM), human PMNL (IC50 = 0.4 microM) and human whole blood (IC50 = 0.9 microM).",5-lipoxygenase inhibitory activity of zileuton. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848634/),μM,0.4,38807,DB01005,Hydroxyurea
,1848634,IC50,"It also inhibited leukotriene (LT)B4 biosynthesis by rat PMNL (IC50 = 0.4 microM), human PMNL (IC50 = 0.4 microM) and human whole blood (IC50 = 0.9 microM).",5-lipoxygenase inhibitory activity of zileuton. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848634/),μM,0.9,38808,DB01005,Hydroxyurea
,1848634,ED50,"In a similar ex vivo study in the rat, the compound displayed an p.o. ED50 of 2 mg/kg.",5-lipoxygenase inhibitory activity of zileuton. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848634/),[mg] / [kg],2,38809,DB01005,Hydroxyurea
,1848634,ED50,Zileuton was highly effective in preventing 6-sulfidopeptide LT formation in the rat peritoneal cavity triggered by an antigen-antibody reaction with an ED50 of 3 mg/kg.,5-lipoxygenase inhibitory activity of zileuton. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848634/),[mg] / [kg],3,38810,DB01005,Hydroxyurea
,1848634,ED50,"In experimental models of inflammation, zileuton significantly reduced arachidonic-acid induced mouse ear edema (ED50 = 31 mg/kg) and also attenuated inflammatory cell accumulation in the rat pleural Arthus reaction.",5-lipoxygenase inhibitory activity of zileuton. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1848634/),[mg] / [kg],31,38811,DB01005,Hydroxyurea
,8620677,time to reach the maximum plasma concentration,"Although the mean time to reach the maximum plasma concentration for digoxin was significantly shorter after concomitant administration of digoxin and zileuton than after concomitant administration of digoxin and placebo (0.95 vs 1.43 hours), there were no significant differences between the 2 regimens in the values for maximum plasma concentration, area under the plasma concentration-time curve from 0 to 24 hours, elimination half-life, oral clearance, and apparent volume of distribution associated with the terminal phase.",Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620677/),h,0.95,40175,DB01005,Hydroxyurea
,8620677,time to reach the maximum plasma concentration,"Although the mean time to reach the maximum plasma concentration for digoxin was significantly shorter after concomitant administration of digoxin and zileuton than after concomitant administration of digoxin and placebo (0.95 vs 1.43 hours), there were no significant differences between the 2 regimens in the values for maximum plasma concentration, area under the plasma concentration-time curve from 0 to 24 hours, elimination half-life, oral clearance, and apparent volume of distribution associated with the terminal phase.",Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620677/),h,1.43,40176,DB01005,Hydroxyurea
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1404,43042,DB01005,Hydroxyurea
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1374,43043,DB01005,Hydroxyurea
,18781906,trough levels,"Mean imatinib trough levels in patients not receiving AEDs ( 1404 ng/ml, CV 64%) and on non-EIAEDs (1374 ng/ml, CV 46%) were comparable with mean imatinib trough levels of the historical control group of CML patients (1400 ng/ml, CV 50%).",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],1400,43044,DB01005,Hydroxyurea
,18781906,trough levels,"Mean trough levels of imatinib were reduced up to 2.9-fold (477 ng/ml, CV 70%) in patients treated with EIAEDs.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],477,43045,DB01005,Hydroxyurea
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],240,43046,DB01005,Hydroxyurea
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],351,43047,DB01005,Hydroxyurea
,18781906,trough level,"Only slight, but although significant differences were observed in the mean trough level of the metabolite CGP74588 between EIAED-, non-EIAED and no-AED patients, 240 ng/ml (CV 57%), 351 ng/ml (CV 34%) and 356 ng/ml (CV 52%), respectively.",Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18781906/),[ng] / [ml],356,43048,DB01005,Hydroxyurea
,6941040,drug dose required for 90% inhibition of CFU,CML CFUc were significantly more sensitive to Ara-C [drug dose required for 90% inhibition of CFUc growth (LD90) = 0.015 +/- 0.003 microgram/ml] than were normal CFUc (LD90 = 0.038 +/- 0.009 microgram/ml).,Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6941040/),[μg] / [ml],0.015,43815,DB01005,Hydroxyurea
,6941040,LD90,CML CFUc were significantly more sensitive to Ara-C [drug dose required for 90% inhibition of CFUc growth (LD90) = 0.015 +/- 0.003 microgram/ml] than were normal CFUc (LD90 = 0.038 +/- 0.009 microgram/ml).,Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6941040/),[μg] / [ml],0.038,43816,DB01005,Hydroxyurea
,8620666,half-life (t1/2),"A slight but statistically significant increase in the mean half-life (t1/2) of prednisolone was detected with zileuton + prednisone administration compared with prednisone + placebo (from 2.8 to 2.9 hours); however, this change was of no clinical relevance.",Pharmacokinetic interactions between zileuton and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620666/),h,2.8,45223,DB01005,Hydroxyurea
,8620666,half-life (t1/2),"A slight but statistically significant increase in the mean half-life (t1/2) of prednisolone was detected with zileuton + prednisone administration compared with prednisone + placebo (from 2.8 to 2.9 hours); however, this change was of no clinical relevance.",Pharmacokinetic interactions between zileuton and prednisone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620666/),h,2.9,45224,DB01005,Hydroxyurea
,8620666,0 to 6 hours (AUC0-6),"While the single 40mg dose of prednisone resulted in a slight but statistically significant decrease in the mean zileuton AUC value from 0 to 6 hours (AUC0-6) [from 23 to 20 mg/L/h] and a reduction in tMAX (from 2.3 to 1.7 hours), these results were not considered to be clinically significant.",Pharmacokinetic interactions between zileuton and prednisone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620666/),[mg] / [h·l],23,45225,DB01005,Hydroxyurea
,8620666,0 to 6 hours (AUC0-6),"While the single 40mg dose of prednisone resulted in a slight but statistically significant decrease in the mean zileuton AUC value from 0 to 6 hours (AUC0-6) [from 23 to 20 mg/L/h] and a reduction in tMAX (from 2.3 to 1.7 hours), these results were not considered to be clinically significant.",Pharmacokinetic interactions between zileuton and prednisone. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620666/),[mg] / [h·l],20,45226,DB01005,Hydroxyurea
,8620671,clearance,"The clearance of total zileuton (unbound plus bound to plasma proteins) in patients with hepatic impairment (approximately 350 ml/min) was approximately half than in healthy subjects (approximately 670 ml/min), with similar values in patients with mild or moderate cirrhosis.",The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620671/),[ml] / [min],350,62272,DB01005,Hydroxyurea
,8620671,clearance,"The clearance of total zileuton (unbound plus bound to plasma proteins) in patients with hepatic impairment (approximately 350 ml/min) was approximately half than in healthy subjects (approximately 670 ml/min), with similar values in patients with mild or moderate cirrhosis.",The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620671/),[ml] / [min],670,62273,DB01005,Hydroxyurea
,8147271,IC50,"Zileuton (2 mg/kg) was extremely bioavailable in dogs (> 10 microM plasma concentrations), and inhibited the A23187-induced ex vivo production of LTB4 by venous blood by > 90%, in concordance with its potency in canine blood in vitro (IC50 = 1.1 microM).",Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147271/),μM,1.1,69341,DB01005,Hydroxyurea
,8147271,peak plasma concentrations,"Significant inhibition of ex vivo LTB4 synthesis was also observed at this dose (49%), in accord with peak plasma concentrations of 0.5 microM and an in vitro potency of 0.2-0.4 microM (IC50) in whole blood from these animals.",Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147271/),μM,0.5,69342,DB01005,Hydroxyurea
,8147271,potency,"Significant inhibition of ex vivo LTB4 synthesis was also observed at this dose (49%), in accord with peak plasma concentrations of 0.5 microM and an in vitro potency of 0.2-0.4 microM (IC50) in whole blood from these animals.",Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147271/),μM,0.2-0.4,69343,DB01005,Hydroxyurea
,8147271,IC50,"Significant inhibition of ex vivo LTB4 synthesis was also observed at this dose (49%), in accord with peak plasma concentrations of 0.5 microM and an in vitro potency of 0.2-0.4 microM (IC50) in whole blood from these animals.",Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8147271/),μM,0.2-0.4,69344,DB01005,Hydroxyurea
,25970508,Extraction efficiency,"Extraction efficiency for 1-, 5-, 10-, and 50-mcg/mL samples averaged 2.2%, 1.8%, 1.6%, and 1.4%, respectively.",Isotope-dilution gas chromatography-mass spectrometry method for the analysis of hydroxyurea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25970508/),%,2.2,72868,DB01005,Hydroxyurea
,25970508,Extraction efficiency,"Extraction efficiency for 1-, 5-, 10-, and 50-mcg/mL samples averaged 2.2%, 1.8%, 1.6%, and 1.4%, respectively.",Isotope-dilution gas chromatography-mass spectrometry method for the analysis of hydroxyurea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25970508/),%,1.8,72869,DB01005,Hydroxyurea
,25970508,Extraction efficiency,"Extraction efficiency for 1-, 5-, 10-, and 50-mcg/mL samples averaged 2.2%, 1.8%, 1.6%, and 1.4%, respectively.",Isotope-dilution gas chromatography-mass spectrometry method for the analysis of hydroxyurea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25970508/),%,1.6,72870,DB01005,Hydroxyurea
,25970508,Extraction efficiency,"Extraction efficiency for 1-, 5-, 10-, and 50-mcg/mL samples averaged 2.2%, 1.8%, 1.6%, and 1.4%, respectively.",Isotope-dilution gas chromatography-mass spectrometry method for the analysis of hydroxyurea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25970508/),%,1.4,72871,DB01005,Hydroxyurea
,11459996,plasma:peritoneal fluid concentration ratio,The steady-state HU plasma:peritoneal fluid concentration ratio ranged from 1.06 x 10(3) to 1.25 x 10(3) and the plasma HU clearance ranged from 4.63 to 5.81 l/h/m(2).,Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),,1.06 x 10(3),74233,DB01005,Hydroxyurea
,11459996,plasma:peritoneal fluid concentration ratio,The steady-state HU plasma:peritoneal fluid concentration ratio ranged from 1.06 x 10(3) to 1.25 x 10(3) and the plasma HU clearance ranged from 4.63 to 5.81 l/h/m(2).,Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),,1.25 x 10(3),74234,DB01005,Hydroxyurea
,11459996,clearance,The steady-state HU plasma:peritoneal fluid concentration ratio ranged from 1.06 x 10(3) to 1.25 x 10(3) and the plasma HU clearance ranged from 4.63 to 5.81 l/h/m(2).,Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),[h·l] / [m(2],4.63,74235,DB01005,Hydroxyurea
,11459996,Peritoneal fluid,"Peritoneal fluid AUC = 137,639 +/- 43,914 microg/ml x min, t(1/2) = 100.9 +/- 56.4 min and Cl = 25.29 +/- 10.88 ml/min.",Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),[μg] / [min·ml],"137,639",74236,DB01005,Hydroxyurea
,11459996,AUC,"Peritoneal fluid AUC = 137,639 +/- 43,914 microg/ml x min, t(1/2) = 100.9 +/- 56.4 min and Cl = 25.29 +/- 10.88 ml/min.",Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),[μg] / [min·ml],"137,639",74237,DB01005,Hydroxyurea
,11459996,t(1/2),"Peritoneal fluid AUC = 137,639 +/- 43,914 microg/ml x min, t(1/2) = 100.9 +/- 56.4 min and Cl = 25.29 +/- 10.88 ml/min.",Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),min,100.9,74238,DB01005,Hydroxyurea
,11459996,Cl,"Peritoneal fluid AUC = 137,639 +/- 43,914 microg/ml x min, t(1/2) = 100.9 +/- 56.4 min and Cl = 25.29 +/- 10.88 ml/min.",Phase I and pharmacologic study of i.v. hydroxyurea infusion given with i.p. 5-fluoro-2'-deoxyuridine and leucovorin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11459996/),[ml] / [min],25.29,74239,DB01005,Hydroxyurea
,9311617,V(max),"The V(max) values ranged from 0.02 to 7.9 nmol/min/mg microsomal protein, a 400-fold difference, whereas K(M) ranged from 204 to 2500 microM, only a 12-fold difference.",Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311617/),[nM] / [mg·min],0.02 to 7.9,77723,DB01005,Hydroxyurea
,9311617,K(M),"The V(max) values ranged from 0.02 to 7.9 nmol/min/mg microsomal protein, a 400-fold difference, whereas K(M) ranged from 204 to 2500 microM, only a 12-fold difference.",Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9311617/),μM,204 to 2500,77724,DB01005,Hydroxyurea
,24729271,mean absorption time,The typical mean absorption time was 0.222 hour.,Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24729271/),h,0.222,96861,DB01005,Hydroxyurea
,24729271,apparent volume of distribution,The typical apparent volume of distribution was 21.8 L and the apparent systemic clearance was 6.88 L/h for an average weight patient of 30.7 kg.,Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24729271/),l,21.8,96862,DB01005,Hydroxyurea
,24729271,apparent systemic clearance,The typical apparent volume of distribution was 21.8 L and the apparent systemic clearance was 6.88 L/h for an average weight patient of 30.7 kg.,Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24729271/),[l] / [h],6.88,96863,DB01005,Hydroxyurea
,7850924,maximal elimination rate (Vmax),"For the combined intravenous and oral data set, these parameters were estimated to be: maximal elimination rate (Vmax), 0.097 mmol h-1 l-1; Michaelis constant for HU elimination (KM), 0.323 mmol/l; renal clearance (ClR), 90.8 ml/min; volume of distribution (Vd), 0.186 x (body weight) + 25.4 l; absorption rate constant (Ka), 2.92 h-1; and availability to the systemic circulation (F), 0.792.",Population pharmacokinetics of hydroxyurea in cancer patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850924/),[mM] / [h·l],0.097,100637,DB01005,Hydroxyurea
,7850924,Michaelis constant for,"For the combined intravenous and oral data set, these parameters were estimated to be: maximal elimination rate (Vmax), 0.097 mmol h-1 l-1; Michaelis constant for HU elimination (KM), 0.323 mmol/l; renal clearance (ClR), 90.8 ml/min; volume of distribution (Vd), 0.186 x (body weight) + 25.4 l; absorption rate constant (Ka), 2.92 h-1; and availability to the systemic circulation (F), 0.792.",Population pharmacokinetics of hydroxyurea in cancer patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850924/),[mM] / [l],0.323,100638,DB01005,Hydroxyurea
,7850924,renal clearance (ClR),"For the combined intravenous and oral data set, these parameters were estimated to be: maximal elimination rate (Vmax), 0.097 mmol h-1 l-1; Michaelis constant for HU elimination (KM), 0.323 mmol/l; renal clearance (ClR), 90.8 ml/min; volume of distribution (Vd), 0.186 x (body weight) + 25.4 l; absorption rate constant (Ka), 2.92 h-1; and availability to the systemic circulation (F), 0.792.",Population pharmacokinetics of hydroxyurea in cancer patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850924/),[ml] / [min],90.8,100639,DB01005,Hydroxyurea
,7850924,volume of distribution (Vd),"For the combined intravenous and oral data set, these parameters were estimated to be: maximal elimination rate (Vmax), 0.097 mmol h-1 l-1; Michaelis constant for HU elimination (KM), 0.323 mmol/l; renal clearance (ClR), 90.8 ml/min; volume of distribution (Vd), 0.186 x (body weight) + 25.4 l; absorption rate constant (Ka), 2.92 h-1; and availability to the systemic circulation (F), 0.792.",Population pharmacokinetics of hydroxyurea in cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850924/),,0.186,100640,DB01005,Hydroxyurea
,7850924,volume of distribution (Vd),"For the combined intravenous and oral data set, these parameters were estimated to be: maximal elimination rate (Vmax), 0.097 mmol h-1 l-1; Michaelis constant for HU elimination (KM), 0.323 mmol/l; renal clearance (ClR), 90.8 ml/min; volume of distribution (Vd), 0.186 x (body weight) + 25.4 l; absorption rate constant (Ka), 2.92 h-1; and availability to the systemic circulation (F), 0.792.",Population pharmacokinetics of hydroxyurea in cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850924/),l,25.4,100641,DB01005,Hydroxyurea
,7850924,absorption rate constant (Ka),"For the combined intravenous and oral data set, these parameters were estimated to be: maximal elimination rate (Vmax), 0.097 mmol h-1 l-1; Michaelis constant for HU elimination (KM), 0.323 mmol/l; renal clearance (ClR), 90.8 ml/min; volume of distribution (Vd), 0.186 x (body weight) + 25.4 l; absorption rate constant (Ka), 2.92 h-1; and availability to the systemic circulation (F), 0.792.",Population pharmacokinetics of hydroxyurea in cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850924/),1/[h],2.92,100642,DB01005,Hydroxyurea
,7850924,availability to the systemic circulation (F),"For the combined intravenous and oral data set, these parameters were estimated to be: maximal elimination rate (Vmax), 0.097 mmol h-1 l-1; Michaelis constant for HU elimination (KM), 0.323 mmol/l; renal clearance (ClR), 90.8 ml/min; volume of distribution (Vd), 0.186 x (body weight) + 25.4 l; absorption rate constant (Ka), 2.92 h-1; and availability to the systemic circulation (F), 0.792.",Population pharmacokinetics of hydroxyurea in cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850924/),,0.792,100643,DB01005,Hydroxyurea
,31106898,Time to MTD,"Time to MTD was 4.8 months (IQR 3.3-9.3), significantly shorter than comparison studies (p < 0.0001), thus meeting the primary endpoint.",Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31106898/),month,4.8,100782,DB01005,Hydroxyurea
,17944539,half-life,"The stability studies revealed the half-life of M1 to be about 0.85 h in HSA, 1.82 h in human plasma, and 4.48 h in phosphate-buffered saline (PBS) as determined by first-order approximation.",Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),h,0.85,103134,DB01005,Hydroxyurea
,17944539,half-life,"The stability studies revealed the half-life of M1 to be about 0.85 h in HSA, 1.82 h in human plasma, and 4.48 h in phosphate-buffered saline (PBS) as determined by first-order approximation.",Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),h,1.82,103135,DB01005,Hydroxyurea
,17944539,half-life,"The stability studies revealed the half-life of M1 to be about 0.85 h in HSA, 1.82 h in human plasma, and 4.48 h in phosphate-buffered saline (PBS) as determined by first-order approximation.",Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),h,4.48,103136,DB01005,Hydroxyurea
,17944539,rate constant k,The alkylation rate constant k for HSA was 20 M(-1) min(-1).,Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17944539/),1/[M·min],20,103137,DB01005,Hydroxyurea
,8996529,renal,"The mean +/- SE renal and nonrenal clearances of hydroxyurea were 2.14 +/- 0.18 and 3.39 +/- 0.28 l/h per m2 (n = 16), neither of which correlated with the dose.",Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996529/),[l] / [h·m2],2.14,108709,DB01005,Hydroxyurea
,8996529,nonrenal clearances,"The mean +/- SE renal and nonrenal clearances of hydroxyurea were 2.14 +/- 0.18 and 3.39 +/- 0.28 l/h per m2 (n = 16), neither of which correlated with the dose.",Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996529/),[l] / [h·m2],3.39,108710,DB01005,Hydroxyurea
,8996529,half-life,The concentration of hydroxyurea in plasma decayed monoexponentially with a mean +/- SE half-life of 3.25 +/- 0.18 h (n = 17).,Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996529/),h,3.25,108711,DB01005,Hydroxyurea
>,8996529,steady-state concentration,"The steady-state concentration of hydroxyurea was > 200 microM in all nine patients treated at 2 g/m2 per day, a dose which was well tolerated for 5 days.",Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8996529/),μM,200,108712,DB01005,Hydroxyurea
,9625466,ratio of the,"Orally administered fenleuton (four 5 mg kg(-1) doses, given once daily) was absorbed from the gastrointestinal tract, and penetrated readily into tissue cage exudate, the ratio of the plasma:exudate AUC0-48h being 0.90+/-0.02 (n=6).","Pharmacokinetics and pharmacodynamics of fenleuton, a 5-lipoxygenase inhibitor, in ponies. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625466/),,0.90,116007,DB01005,Hydroxyurea
,31623213,area under the curve (AUC),None of the nine children reached the therapeutic target defined by Dong et al. as an area under the curve (AUC) = 115 h.mg/L; four patients were suspected to be non-compliant.,Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31623213/),[h·mg] / [l],115,133607,DB01005,Hydroxyurea
,32862024,m/z,"Detection was done in selected reaction monitoring (SRM) mode with m/z 77.1 > 44.4 and m/z 75.1 > 58.2 for HU and methylurea (internal standard), respectively.",A highly sensitive UPLC-MS/MS method for hydroxyurea to assess pharmacokinetic intervention by phytotherapeutics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32862024/),,77.1,137170,DB01005,Hydroxyurea
>,32862024,m/z,"Detection was done in selected reaction monitoring (SRM) mode with m/z 77.1 > 44.4 and m/z 75.1 > 58.2 for HU and methylurea (internal standard), respectively.",A highly sensitive UPLC-MS/MS method for hydroxyurea to assess pharmacokinetic intervention by phytotherapeutics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32862024/),,44.4,137171,DB01005,Hydroxyurea
>,32862024,m/z,"Detection was done in selected reaction monitoring (SRM) mode with m/z 77.1 > 44.4 and m/z 75.1 > 58.2 for HU and methylurea (internal standard), respectively.",A highly sensitive UPLC-MS/MS method for hydroxyurea to assess pharmacokinetic intervention by phytotherapeutics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32862024/),,75.1,137172,DB01005,Hydroxyurea
>,32862024,m/z,"Detection was done in selected reaction monitoring (SRM) mode with m/z 77.1 > 44.4 and m/z 75.1 > 58.2 for HU and methylurea (internal standard), respectively.",A highly sensitive UPLC-MS/MS method for hydroxyurea to assess pharmacokinetic intervention by phytotherapeutics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32862024/),,58.2,137173,DB01005,Hydroxyurea
,7858290,t1/2,A plasma concentration of 159 microM was achieved and a t1/2 of 11.3 min determined.,Pharmacokinetics of hydroxyurea in nude mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7858290/),min,11.3,141282,DB01005,Hydroxyurea
,3436742,half-life,The drug was cleared rapidly from the blood compartment with a half-life of 2.5 min and a total body clearance of 11.51/min/m2.,Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3436742/),min,2.5,145863,DB01005,Hydroxyurea
,3436742,total body clearance,The drug was cleared rapidly from the blood compartment with a half-life of 2.5 min and a total body clearance of 11.51/min/m2.,Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3436742/),1/[m2·min],11.51,145864,DB01005,Hydroxyurea
,3436742,maximum tolerated dose,"The dose-limiting toxicity of caracemide using the 4 h infusion was an intolerable ""burning pain"" with a maximum tolerated dose of 795 mg/m2.",Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3436742/),[mg] / [m2],795,145865,DB01005,Hydroxyurea
,9923573,terminal phase t1/2,The mean values for the terminal phase t1/2 were 16-17 h after multiple-dose administration.,Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923573/),h,16-17,150511,DB01005,Hydroxyurea
,9923573,Cl(f),"When normalized for body weight, the mean day 8 Cl(f) values for 50-, 100-mg, and 150-mg doses were 0.57 (n=13), 0.51 (n=10), and 0.43 (n=1) ml x min(-1) x kg(-1), respectively, while the mean Vz/f values ranged from 0.75 to 0.77 l x kg(-1).",Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923573/),[ml] / [kg·min],0.57,150512,DB01005,Hydroxyurea
,9923573,Cl(f),"When normalized for body weight, the mean day 8 Cl(f) values for 50-, 100-mg, and 150-mg doses were 0.57 (n=13), 0.51 (n=10), and 0.43 (n=1) ml x min(-1) x kg(-1), respectively, while the mean Vz/f values ranged from 0.75 to 0.77 l x kg(-1).",Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923573/),[ml] / [kg·min],0.51,150513,DB01005,Hydroxyurea
,9923573,Cl(f),"When normalized for body weight, the mean day 8 Cl(f) values for 50-, 100-mg, and 150-mg doses were 0.57 (n=13), 0.51 (n=10), and 0.43 (n=1) ml x min(-1) x kg(-1), respectively, while the mean Vz/f values ranged from 0.75 to 0.77 l x kg(-1).",Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923573/),[ml] / [kg·min],0.43,150514,DB01005,Hydroxyurea
,9923573,Vz/f,"When normalized for body weight, the mean day 8 Cl(f) values for 50-, 100-mg, and 150-mg doses were 0.57 (n=13), 0.51 (n=10), and 0.43 (n=1) ml x min(-1) x kg(-1), respectively, while the mean Vz/f values ranged from 0.75 to 0.77 l x kg(-1).",Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923573/),[l] / [kg],0.75 to 0.77,150515,DB01005,Hydroxyurea
,9923573,accumulation ratio,"The mean accumulation ratio observed (day 8 to day 1 AUC0-24 ratio) of ABT-761 was approximately 1.7, which is consistent with the t1/2 of this drug.",Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9923573/),,1.7,150516,DB01005,Hydroxyurea
,9667246,MTD,The MTD of HU given as a 24-hour infusion was 27 g/m2.,Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9667246/),[g] / [m2],27,160656,DB01005,Hydroxyurea
,8620668,park plasma concentration (Cmax),"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),[mg] / [l],3.07,160969,DB01005,Hydroxyurea
,8620668,time to Cmax,"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),[mg] / [l],4.37,160970,DB01005,Hydroxyurea
,8620668,time to Cmax,"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),h,1.5,160971,DB01005,Hydroxyurea
,8620668,time to Cmax,"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),[ml] / [min],793,160972,DB01005,Hydroxyurea
,8620668,apparent total plasma clearance,"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),[mg] / [l],4.37,160973,DB01005,Hydroxyurea
,8620668,apparent total plasma clearance,"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),h,1.5,160974,DB01005,Hydroxyurea
,8620668,apparent total plasma clearance,"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),[ml] / [min],793,160975,DB01005,Hydroxyurea
,8620668,apparent total plasma clearance,"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),[l] / [h],47.6,160976,DB01005,Hydroxyurea
,8620668,apparent terminal phase volume of distribution,"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),[ml] / [min],579,160977,DB01005,Hydroxyurea
,8620668,apparent terminal phase volume of distribution,"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),[l] / [h],47.6,160978,DB01005,Hydroxyurea
,8620668,apparent terminal phase volume of distribution,"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),[l] / [h],34.7,160979,DB01005,Hydroxyurea
,8620668,apparent terminal phase volume of distribution,"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),l,179,160980,DB01005,Hydroxyurea
,8620668,apparent terminal phase volume of distribution,"Steady-state park plasma concentration (Cmax), time to Cmax, apparent total plasma clearance, and apparent terminal phase volume of distribution values after the q8h and q6h regimens were 3.07 +/- 1.13 and 4.37 +/- 1.02 mg/L, 1.5 +/- 0.9 and 1.5 +/- 0.9 hours, 793 +/- 233 and 579 +/- 162 ml/min (47.6 and 34.7 L/h), and 179 +/- 126 and 115 +/- 29L, respectively (mean +/- SD).",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),l,115,160981,DB01005,Hydroxyurea
above,8620668,trough plasma concentrations,"The q6h regimen of zileuton 600mg was superior to the q8h regimen in maintaining trough plasma concentrations of zileuton above 1.5 mg/L, corresponding to approximately 70 to 80% inhibition of leukotriene B4 biosynthesis.",Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620668/),[mg] / [l],1.5,160982,DB01005,Hydroxyurea
,11240742,survival,The median survival was 11.3 months.,Long-term results and pharmacokinetics of high-dose paclitaxel in patients with refractory epithelial ovarian carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11240742/),month,11.3,161284,DB01005,Hydroxyurea
,7853186,IC50,A-79175 was a potent selective inhibitor of 5-hydroxyeicosatetraenoic acid formation in rat basophilic leukemic homogenates (IC50 = 54 nM) and of calcium ionophore-induced leukotriene B4 (LTB4) formation in purified human polymorphonuclear leukocytes (IC50 = 25 nM) and human whole blood (IC50 = 80 nM).,Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853186/),nM,54,162165,DB01005,Hydroxyurea
,7853186,IC50,A-79175 was a potent selective inhibitor of 5-hydroxyeicosatetraenoic acid formation in rat basophilic leukemic homogenates (IC50 = 54 nM) and of calcium ionophore-induced leukotriene B4 (LTB4) formation in purified human polymorphonuclear leukocytes (IC50 = 25 nM) and human whole blood (IC50 = 80 nM).,Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853186/),nM,25,162166,DB01005,Hydroxyurea
,7853186,IC50,A-79175 was a potent selective inhibitor of 5-hydroxyeicosatetraenoic acid formation in rat basophilic leukemic homogenates (IC50 = 54 nM) and of calcium ionophore-induced leukotriene B4 (LTB4) formation in purified human polymorphonuclear leukocytes (IC50 = 25 nM) and human whole blood (IC50 = 80 nM).,Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853186/),nM,80,162167,DB01005,Hydroxyurea
,7853186,oral ED50s,The compound inhibited LT formation in the rat with oral ED50s of 1 to 2 mg/kg.,Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853186/),[mg] / [kg],1 to 2,162168,DB01005,Hydroxyurea
,7853186,elimination half-life,A-79175 was resistant to glucuronidation and had an elimination half-life of nearly 9 hr in cynomolgus monkeys.,Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7853186/),h,9,162169,DB01005,Hydroxyurea
,12439592,maximum tolerated dose,The gemcitabine maximum tolerated dose was established at 750 mg/m(2) on days 2 and 9.,Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12439592/),mg,750,164423,DB01005,Hydroxyurea
,19248046,MTD,The MTD of vatalanib for all patients was 1000 mg twice-a-day.,Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19248046/),mg,1000,168805,DB01005,Hydroxyurea
,1737352,t1/2,"The median rate of ara-CTP elimination was slightly faster after fludarabine treatment (t1/2, 6.7 versus 5.8 h), suggesting that catabolism of ara-CTP was not responsible for the increased ara-CTP area under the curve.",Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1737352/),h,6.7,170083,DB01005,Hydroxyurea
,1737352,t1/2,"The median rate of ara-CTP elimination was slightly faster after fludarabine treatment (t1/2, 6.7 versus 5.8 h), suggesting that catabolism of ara-CTP was not responsible for the increased ara-CTP area under the curve.",Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1737352/),h,5.8,170084,DB01005,Hydroxyurea
,21619673,clearance,"The median (and interindividual coefficient of variation (CV)) of clearance was 11.6 L/h (30%), the central volume was 45.3 L (35%).","Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21619673/),[l] / [h],11.6,173400,DB01005,Hydroxyurea
,21619673,central volume,"The median (and interindividual coefficient of variation (CV)) of clearance was 11.6 L/h (30%), the central volume was 45.3 L (35%).","Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21619673/),l,45.3,173401,DB01005,Hydroxyurea
,11805220,K(i),"SC-57461A (3-[methyl[3-[4-phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl) is a potent inhibitor of human recombinant LTA(4) hydrolase (epoxide hydrolase and aminopeptidase activities, K(i) values = 23 and 27 nM, respectively) as well as calcium ionophore-induced LTB(4) production in human whole blood (IC(50) = 49 nM).","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),nM,23,176267,DB01005,Hydroxyurea
,11805220,K(i),"SC-57461A (3-[methyl[3-[4-phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl) is a potent inhibitor of human recombinant LTA(4) hydrolase (epoxide hydrolase and aminopeptidase activities, K(i) values = 23 and 27 nM, respectively) as well as calcium ionophore-induced LTB(4) production in human whole blood (IC(50) = 49 nM).","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),nM,27,176268,DB01005,Hydroxyurea
,11805220,IC(50),"SC-57461A (3-[methyl[3-[4-phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl) is a potent inhibitor of human recombinant LTA(4) hydrolase (epoxide hydrolase and aminopeptidase activities, K(i) values = 23 and 27 nM, respectively) as well as calcium ionophore-induced LTB(4) production in human whole blood (IC(50) = 49 nM).","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),nM,49,176269,DB01005,Hydroxyurea
,11805220,ED(50),"Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),h,1.0,176270,DB01005,Hydroxyurea
,11805220,ED(50),"Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),h,3.0,176271,DB01005,Hydroxyurea
,11805220,ED(50),"Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),[mg] / [kg],0.2,176272,DB01005,Hydroxyurea
,11805220,ED(50),"Oral activity was evident from the ability of the compound to inhibit mouse ex vivo calcium ionophore-stimulated blood LTB(4) production with ED(50) values at 1.0 and 3.0 h of 0.2 and 0.8 mg/kg, respectively.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),[mg] / [kg],0.8,176273,DB01005,Hydroxyurea
,11805220,ED(50),"In a rat model of ionophore-induced peritoneal eicosanoid production, SC-57461 inhibited LTB(4) production in a dose-dependent manner (ED(50) = 0.3-1 mg/kg) without affecting LTC(4) or 6-keto-prostaglandin F(1alpha) production.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),[mg] / [kg],0.3-1,176274,DB01005,Hydroxyurea
,11805220,ED(90),"Oral pretreatment with SC-57461 in a rat reversed passive dermal Arthus model blocked LTB(4) production with an ED(90) value of 3 to 10 mg/kg, demonstrating good penetration of drug into skin.","Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11805220/),[mg] / [kg],3 to 10,176275,DB01005,Hydroxyurea
,8852387,peak concentration (Cmax),Mean (+/- standard deviation) peak concentration (Cmax) was 0.135 +/- 0.06 mmol/L and mean trough level (Cmin) was 0.0085 +/- 0.003 mmol/L.,Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852387/),[mM] / [l],0.135,191032,DB01005,Hydroxyurea
,8852387,trough level (Cmin),Mean (+/- standard deviation) peak concentration (Cmax) was 0.135 +/- 0.06 mmol/L and mean trough level (Cmin) was 0.0085 +/- 0.003 mmol/L.,Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852387/),[mM] / [l],0.0085,191033,DB01005,Hydroxyurea
,8852387,concentration at steady state,Mean concentration at steady state was 0.045 +/- 0.006 mmol/L.,Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852387/),[mM] / [l],0.045,191034,DB01005,Hydroxyurea
,8852387,Apparent clearance (Cl/F),"Apparent clearance (Cl/F) was 0.18 +/- 0.005 L/hr/kg, and half-life (t1/2) was 2.5 +/- 0.5 hours.",Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852387/),[l] / [h·kg],0.18,191035,DB01005,Hydroxyurea
,8852387,half-life (t1/2),"Apparent clearance (Cl/F) was 0.18 +/- 0.005 L/hr/kg, and half-life (t1/2) was 2.5 +/- 0.5 hours.",Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852387/),h,2.5,191036,DB01005,Hydroxyurea
,8852387,tmax,"Hydroxyurea given orally to patients infected with HIV-1 was well absorbed from the gastrointestinal tract, with a tmax of 0.85 to 0.96 hours after ingestion.",Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852387/),h,0.85 to 0.96,191037,DB01005,Hydroxyurea
,7397621,maximal tolerated dose (MTD),The maximal tolerated dose (MTD) was 800 mg/m2 every 4 hours for the oral route and 3.0 mg/m2/min x 72 hours for IV infusion.,"Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7397621/),[mg] / [m2],800,195677,DB01005,Hydroxyurea
,7397621,maximal tolerated dose (MTD),The maximal tolerated dose (MTD) was 800 mg/m2 every 4 hours for the oral route and 3.0 mg/m2/min x 72 hours for IV infusion.,"Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7397621/),[mg] / [m2·min],3.0,195678,DB01005,Hydroxyurea
,9473217,Oral bioavailability (F),Oral bioavailability (F) averaged 108%.,A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9473217/),%,108,199623,DB01005,Hydroxyurea
,9473217,time in which,The time in which maximum plasma concentrations (Cmax) were achieved averaged 1.22 hours with an average lag time of 0.22 hours after oral administration.,A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9473217/),h,1.22,199624,DB01005,Hydroxyurea
,9473217,maximum plasma concentrations (Cmax),The time in which maximum plasma concentrations (Cmax) were achieved averaged 1.22 hours with an average lag time of 0.22 hours after oral administration.,A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9473217/),h,1.22,199625,DB01005,Hydroxyurea
,9473217,lag time,The time in which maximum plasma concentrations (Cmax) were achieved averaged 1.22 hours with an average lag time of 0.22 hours after oral administration.,A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9473217/),h,0.22,199626,DB01005,Hydroxyurea
,9473217,half-lives,"The initial harmonic mean half-lives for oral and IV hydroxyurea were 1.78 and 0.63 hours, respectively, and the harmonic mean terminal half-lives were 3.32 and 3.39 hours, respectively.",A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9473217/),h,1.78,199627,DB01005,Hydroxyurea
,9473217,half-lives,"The initial harmonic mean half-lives for oral and IV hydroxyurea were 1.78 and 0.63 hours, respectively, and the harmonic mean terminal half-lives were 3.32 and 3.39 hours, respectively.",A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9473217/),h,0.63,199628,DB01005,Hydroxyurea
,9473217,terminal half-lives,"The initial harmonic mean half-lives for oral and IV hydroxyurea were 1.78 and 0.63 hours, respectively, and the harmonic mean terminal half-lives were 3.32 and 3.39 hours, respectively.",A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9473217/),h,3.32,199629,DB01005,Hydroxyurea
,9473217,terminal half-lives,"The initial harmonic mean half-lives for oral and IV hydroxyurea were 1.78 and 0.63 hours, respectively, and the harmonic mean terminal half-lives were 3.32 and 3.39 hours, respectively.",A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9473217/),h,3.39,199630,DB01005,Hydroxyurea
,9473217,systemic clearance,"For IV hydroxyurea, systemic clearance averaged 76.16 mL/min/m2 and the mean volume of distribution at steady-state was 19.71 L/m2, whereas Cloral/F and Voral/F averaged 73.16 mL/min/m2 and 19.65 L/m2, respectively, after oral administration.",A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9473217/),[ml] / [m2·min],76.16,199631,DB01005,Hydroxyurea
,9473217,volume of distribution at steady-state,"For IV hydroxyurea, systemic clearance averaged 76.16 mL/min/m2 and the mean volume of distribution at steady-state was 19.71 L/m2, whereas Cloral/F and Voral/F averaged 73.16 mL/min/m2 and 19.65 L/m2, respectively, after oral administration.",A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9473217/),[l] / [m2],19.71,199632,DB01005,Hydroxyurea
,9473217,Cloral/F,"For IV hydroxyurea, systemic clearance averaged 76.16 mL/min/m2 and the mean volume of distribution at steady-state was 19.71 L/m2, whereas Cloral/F and Voral/F averaged 73.16 mL/min/m2 and 19.65 L/m2, respectively, after oral administration.",A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9473217/),[ml] / [m2·min],73.16,199633,DB01005,Hydroxyurea
,9473217,Voral/F,"For IV hydroxyurea, systemic clearance averaged 76.16 mL/min/m2 and the mean volume of distribution at steady-state was 19.71 L/m2, whereas Cloral/F and Voral/F averaged 73.16 mL/min/m2 and 19.65 L/m2, respectively, after oral administration.",A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9473217/),[l] / [m2],19.65,199634,DB01005,Hydroxyurea
,9542476,observed time to reach maximum concentration,"After single and multiple doses, mean observed time to reach maximum concentration values of ABT-761 ranged from 4.0 to 7.5 hours.",Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542476/),h,4.0 to 7.5,214025,DB01005,Hydroxyurea
,9542476,terminal half-life,"Mean terminal half-life and apparent volume of distribution during the terminal elimination phase of ABT-761 ranged from 15.4 to 17.8 hours and 69.5 to 78.9 L, respectively, and was dose independent.",Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542476/),h,15.4 to 17.8,214026,DB01005,Hydroxyurea
,9542476,apparent volume of distribution during the terminal elimination phase,"Mean terminal half-life and apparent volume of distribution during the terminal elimination phase of ABT-761 ranged from 15.4 to 17.8 hours and 69.5 to 78.9 L, respectively, and was dose independent.",Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542476/),l,69.5 to 78.9,214027,DB01005,Hydroxyurea
,15089767,half-life time (t1/2),"Pharmacokinetics confirmed a mean maximum plasma arsenic concentration (Cpmax) and a half-life time (t1/2) of 6.9 microm and 3.2 h, respectively, in the therapeutic range.",Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089767/),h,3.2,215252,DB01005,Hydroxyurea
,8213344,oral,The compound was found to be a potent long-acting inhibitor of leukotriene formation in vivo in the rat (oral ED50 = 5 mg/kg) and ex vivo in several species.,The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213344/),[mg] / [kg],5,216227,DB01005,Hydroxyurea
,8213344,ED50,The compound was found to be a potent long-acting inhibitor of leukotriene formation in vivo in the rat (oral ED50 = 5 mg/kg) and ex vivo in several species.,The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213344/),[mg] / [kg],5,216228,DB01005,Hydroxyurea
,8213344,elimination half-life,"In addition, the compound exhibits excellent bioavailability in dogs and monkeys with a relatively long elimination half-life in both the species (6 and 3 h, respectively).",The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213344/),h,6,216229,DB01005,Hydroxyurea
,8213344,elimination half-life,"In addition, the compound exhibits excellent bioavailability in dogs and monkeys with a relatively long elimination half-life in both the species (6 and 3 h, respectively).",The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8213344/),h,3,216230,DB01005,Hydroxyurea
,8620674,peak theophylline levels,"During coadministration with zileuton, mean peak theophylline levels rose from 12.14 to 20.99 mg/L (p < 0.001), while the apparent plasma clearance dropped from 3.74 to 1.91 L/h (p < 0.001).",Effect of zileuton on theophylline pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620674/),[mg] / [l],12.14 to 20.99,221409,DB01005,Hydroxyurea
,8620674,apparent plasma clearance,"During coadministration with zileuton, mean peak theophylline levels rose from 12.14 to 20.99 mg/L (p < 0.001), while the apparent plasma clearance dropped from 3.74 to 1.91 L/h (p < 0.001).",Effect of zileuton on theophylline pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620674/),[l] / [h],3,221410,DB01005,Hydroxyurea
,11399864,percentage,"Following intraperitoneal administration of HU at a dose of 10, 50, 100, or 200 mg/kg BW, the mean percentage of HU excreted in the urine of the wild-type and Tg sickle cell mice over 120 min was 84 +/- 6.4% and 50 +/- 8.2%, respectively, indicating a significant difference in the amount of HU excreted in urine in the two kinds of mice.",Pharmacokinetic profile of the anti-sickling hydroxyurea in wild-type and transgenic sickle cell mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11399864/),%,84,222495,DB01005,Hydroxyurea
,11399864,percentage,"Following intraperitoneal administration of HU at a dose of 10, 50, 100, or 200 mg/kg BW, the mean percentage of HU excreted in the urine of the wild-type and Tg sickle cell mice over 120 min was 84 +/- 6.4% and 50 +/- 8.2%, respectively, indicating a significant difference in the amount of HU excreted in urine in the two kinds of mice.",Pharmacokinetic profile of the anti-sickling hydroxyurea in wild-type and transgenic sickle cell mice. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11399864/),%,50,222496,DB01005,Hydroxyurea
,18369577,oral bioavailability,"The oral bioavailability of RBx 7796 in rat and dog was 83 % and 47 %, respectively.",Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18369577/),%,83,223964,DB01005,Hydroxyurea
,18369577,oral bioavailability,"The oral bioavailability of RBx 7796 in rat and dog was 83 % and 47 %, respectively.",Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18369577/),%,47,223965,DB01005,Hydroxyurea
,23986199,area under the curve,"Plasma levels were significantly reduced by 20% in Oatp1b(-/-) mice compared with wild-type (area under the curve of 38.64 or 48.45 μg·h(-1)·ml(-1), respectively) after oral administration, whereas no difference was observed between groups following intravenous administration.",Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23986199/),[μg] / [h·ml],38.64,231810,DB01005,Hydroxyurea
,23986199,area under the curve,"Plasma levels were significantly reduced by 20% in Oatp1b(-/-) mice compared with wild-type (area under the curve of 38.64 or 48.45 μg·h(-1)·ml(-1), respectively) after oral administration, whereas no difference was observed between groups following intravenous administration.",Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23986199/),[μg] / [h·ml],48.45,231811,DB01005,Hydroxyurea
,23986199,Accumulation,"Accumulation in the kidney was significantly decreased by twofold in Oatp1b(-/-) mice (356.9 vs. 748.1 pmol/g), which correlated with a significant decrease in urinary excretion.",Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23986199/),[pM] / [g],356.9,231812,DB01005,Hydroxyurea
,23986199,Accumulation,"Accumulation in the kidney was significantly decreased by twofold in Oatp1b(-/-) mice (356.9 vs. 748.1 pmol/g), which correlated with a significant decrease in urinary excretion.",Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23986199/),[pM] / [g],748.1,231813,DB01005,Hydroxyurea
,7589031,CL/f,"The noncompartmental means of the CL/f, terminal-phase half-life, and V/f of zileuton were approximately 545 ml min-1, 1.4 h, and 64.3 1, respectively.","Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589031/),[ml] / [min],545,233827,DB01005,Hydroxyurea
,7589031,terminal-phase half-life,"The noncompartmental means of the CL/f, terminal-phase half-life, and V/f of zileuton were approximately 545 ml min-1, 1.4 h, and 64.3 1, respectively.","Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589031/),h,1.4,233828,DB01005,Hydroxyurea
,7589031,V/f,"The noncompartmental means of the CL/f, terminal-phase half-life, and V/f of zileuton were approximately 545 ml min-1, 1.4 h, and 64.3 1, respectively.","Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589031/),1,64.3,233829,DB01005,Hydroxyurea
,7589031,CL/f,The estimate of population typical values of the CL/f for a 70-kg person (540 ml min-1) and V/f for a 70-kg person (64.8 1) from the NONMEM analysis were in agreement with the noncompartmental estimates.,"Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589031/),[ml] / [min],540,233830,DB01005,Hydroxyurea
,7589031,V/f,The estimate of population typical values of the CL/f for a 70-kg person (540 ml min-1) and V/f for a 70-kg person (64.8 1) from the NONMEM analysis were in agreement with the noncompartmental estimates.,"Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589031/),1,64.8,233831,DB01005,Hydroxyurea
,9569998,tmax,"The plasma concentration-time profile of ABT-761 indicates that the drug declines in a monoexponential fashion after moderately slow absorption, with a tmax value of approximately 4 h.","Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569998/),h,4,237357,DB01005,Hydroxyurea
,9569998,terminal elimination t1/2,"The terminal elimination t1/2 averaged 15 h, and was dose independent.","Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569998/),h,15,237358,DB01005,Hydroxyurea
>,14570767,IC50,"In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 microM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6alpha-hydroxylation (CYP2C8), diclofenac 4'-hydroxylation (CYP2C9), (S)-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), testosterone 6beta-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,100,238065,DB01005,Hydroxyurea
,14570767,kinact,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238066,DB01005,Hydroxyurea
,14570767,apparent KI,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238067,DB01005,Hydroxyurea
,14570767,kinact/KIratio,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0003,238068,DB01005,Hydroxyurea
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.037,238069,DB01005,Hydroxyurea
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,98.2,238070,DB01005,Hydroxyurea
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0004,238071,DB01005,Hydroxyurea
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.012,238072,DB01005,Hydroxyurea
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,66.6,238073,DB01005,Hydroxyurea
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0002,238074,DB01005,Hydroxyurea
,8620673,pro,"This stereoselective interaction was accompanied by an increase in mean morning (predose) and evening (12-hour postdose) prothrombin times from 17.5 to 19.8 seconds and 17.1 to 19.1 seconds, respectively; the corresponding changes in the placebo group were from 18.1 to 18.8 seconds and 17.3 to 17.5 seconds.",Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8620673/),seconds,17.5 to 19.8,239236,DB01005,Hydroxyurea
,9143867,maximum concentration,The maximum concentration of terfenadine observed in the study was 9.6 ng.,The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9143867/),ng,9.6,250823,DB01005,Hydroxyurea
,8261572,MTD,"The MTD for the 24-h infusion was 13,520 mg/m2 following a bolus of 1,690 mg/m2, and the mean (+/- SD) plasma steady-state concentration was 1.93 +/- 0.52 mM.",A phase I trial of high-dose continuous-infusion hydroxyurea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261572/),[mg] / [m2],"13,520",262275,DB01005,Hydroxyurea
,8261572,plasma steady-state concentration,"The MTD for the 24-h infusion was 13,520 mg/m2 following a bolus of 1,690 mg/m2, and the mean (+/- SD) plasma steady-state concentration was 1.93 +/- 0.52 mM.",A phase I trial of high-dose continuous-infusion hydroxyurea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261572/),mM,1.93,262276,DB01005,Hydroxyurea
,8261572,MTD,"For the 48-h infusion, the MTD was 17,576 mg/m2 following a bolus of 2,197 mg/m2 and the mean steady-state level was 1.43 +/- 0.31 mM.",A phase I trial of high-dose continuous-infusion hydroxyurea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261572/),[mg] / [m2],"17,576",262277,DB01005,Hydroxyurea
,8261572,steady-state level,"For the 48-h infusion, the MTD was 17,576 mg/m2 following a bolus of 2,197 mg/m2 and the mean steady-state level was 1.43 +/- 0.31 mM.",A phase I trial of high-dose continuous-infusion hydroxyurea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8261572/),mM,1.43,262278,DB01005,Hydroxyurea
